Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Javier Chiriboga

Nurse Practitioner Boca Raton, FL Nurse Practitioner

NPI 1811352669 CMS profile 11186196

8545 Jared Way, Boca Raton, FL 33433

Open in the dashboard

General payments

$9,225

520 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Javier Chiriboga of Boca Raton, FL is reported in the CMS Open Payments database as having received $9,225 across 520 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,801 99
2024 General $1,619 96
2023 General $1,932 97
2022 General $2,263 121
2021 General $1,609 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Javier Chiriboga
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Javier Chiriboga were reported at $1,801. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Javier Chiriboga Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,609 $135 $40–$426 $132
2022 $2,263 $152 $48–$470 $149
2023 $1,932 $166 $54–$529 $160
2024 $1,619 $173 $55–$556 $164
2025 $1,801 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. UCB, Inc. $2,268 131 payments
  2. Amgen Inc. $1,030 58 payments
  3. E.R. Squibb & Sons, L.L.C. $828 57 payments
  4. AstraZeneca Pharmaceuticals LP $792 46 payments
  5. Janssen Biotech, Inc. $671 30 payments
  6. Novartis Pharmaceuticals Corporation $604 52 payments
  7. AbbVie, Inc. $603 25 payments
  8. Pfizer Inc. $359 29 payments
  9. Janssen Scientific Affairs, LLC $358 3 payments
  10. Radius Health, Inc. $303 16 payments
  11. Other $1,408 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,225 520 payments
Products named General payments · program years 2021–2025
  1. Cimzia $1,547 94 payments
  2. ORENCIA $828 57 payments
  3. SAPHNELO $792 46 payments
  4. TREMFYA $780 23 payments
  5. Bimzelx $721 37 payments
  6. SIMPONI ARIA $608 13 payments
  7. EVENITY $602 32 payments
  8. Prolia $602 32 payments
  9. STELARA $487 12 payments
  10. COSENTYX $476 38 payments
  11. Other $4,072 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

1,017

Median for Nurse Practitioner: 389

Drug cost

$14,741

Median for Nurse Practitioner: $21,885

Branded share of claims

10.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydroxychloroquine Sulfate Generic 94 $2,707
Colchicine Generic 28 $2,321
Methylprednisolone Generic 259 $2,308
Methotrexate Methotrexate Sodium Brand 93 $2,087
Alendronate Sodium Generic 177 $1,134
Prednisone Generic 124 $933
Allopurinol Generic 89 $894
Folic Acid Generic 48 $660
Sulfasalazine Generic 15 $515
Methotrexate Sodium Methotrexate Sodium/Pf Brand 17 $397

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$947,039

Of which drugs: $326,155

Medicare patients

1,372

Average age 79

Services billed

48,018

937 women, 435 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 48%
Ischemic heart disease 45%
Chronic kidney disease 32%
Depression 32%
Diabetes 30%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 110 9,360 $189,767
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 43 2,306 $31,795
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 35 48 $19,602
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 810 12,889 $9,695
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 414 1,133 $6,016
Methotrexate sodium, 50 mg J9260 Office 19 37 $43
Methotrexate sodium, 5 mg J9250 Office 11 35 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cimzia
  • UCB, Inc. $416
$416 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $195
$195 — —
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $165
$165 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $164
$164 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

520 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record